51764 | Huvepharma NV | Halofuginone hydrobromide (Stenorol) | Additive compositionPreparation of:- halofuginone hydrobromide: 0,6 %
- povidone (polyvinylpyrrolidone): 1 %,
- castor oil (macrogol glycerol ricinoleate): 2 %,
- corn cobs: 96,4 %.
Solid form.Characterisation of the active substanceHalofuginone hydrobromide:- C16H17BrClN3•HBr
- CAS number: 64924-67-0
- trans-(±)-7-bromo-6-chloro-3-[3-(3-hydroxy-2-piperidyl)-2-oxopropyl]-4(3H)-quinazolinone hydrobromide
- Produced by chemical synthesis.
Impurities: cis-isomer ofhalofuginone hydrobromide, cebrazolone, methoxy cebegine and melylcebegine: ≤ 0,5 % each.Total impurities: ≤ 1 %.Analytical methodsFor the determination of halofuginone hydrobromide in the feed additive and premixtures: high performance liquid chromatography coupled with photometric detection (HPLC-UV).For the determination of halofuginone hydrobromide in compound feed:- High performance liquid chromatography coupled with photometric detection (HPLC-UV) – Commission Regulation (EC) No 152/2009 or
- High performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) – EN 17299.
For the determination of halofuginone hydrobromide in tissues: high performance liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). | Chickens for fattening | — | 2 | 3 | 1.In the directions for use of the additive and premixture, the storage conditions and stability to heat treatment shall be indicated.2.Use prohibited at least 3 days before slaughter.3.The additive shall be incorporated in compound feed in the form of a premixture.4.Halofuginone hydrobromide shall not be mixed with other coccidiostats.5.A post-market monitoring program on the resistance of Eimeria spp. to halofuginone hydrobromide shall be planned and executed by the holder of authorisation, in accordance with Commission Regulation (EC) No 429/2008.6.For users of the additive and premixtures, feed business operators shall establish operational procedures and organisational measures to address potential risks resulting from its use. Where those risks cannot be eliminated by such procedures and measures, the additive and premixtures shall be used with personal breathing, eye and skin protective equipment. | 4 February 2034 | - 50 μg halofuginone/kg of wet liver;
- 40 μg halofuginone/kg of wet kidney;
- 3 μg halofuginone/kg of wet muscle;
- 10 μg halofuginone/kg of wet skin/fat.
|